Paris, France · StartupBioptimus is the self-proclaimed "Mistral of Biology," spun out in early 2024 by a team of alumni from Google DeepMind and Owkin, including CEO Jean-Philippe Vert. The company is building what it calls the first universal foundation model for biology. Where large language models were trained on text to learn human language, Bioptimus trains on biological data—DNA sequences, protein structures, cellular imagery, and clinical phenotypes—to infer the underlying rules of life. The ambition is not just better predictions but a unified biological reasoning layer that can simulate outcomes before expensive lab work happens.
By 2026, Bioptimus has moved from a research thesis to early commercial traction. After a $41M Series A in 2025, the company released its first commercial model that can predict how a specific molecule will interact with a human cell with unusually high accuracy. This enables in-silico screening that reduces wet-lab costs and improves hit rates for drug discovery. French pharma leaders such as Sanofi have begun using these models to prioritize compounds and compress early-stage discovery timelines. The product value is immediate: fewer failed experiments, faster candidate selection, and deeper mechanistic insight.
Bioptimus' roadmap focuses on "multi-scale biology," connecting the micro level (genomics and proteomics) to the macro level (patient outcomes and clinical data). Rather than being limited to protein folding, the models aim to bridge across data modalities so a genetic mutation can be linked to disease pathways, tissue behavior, and potential therapeutic interventions. This requires data breadth and regulatory trust, and Bioptimus is building a defensive moat through European data sovereignty. It leverages partnerships with European research hospitals and biobanks to access high-quality patient data that is difficult for US competitors to acquire under GDPR constraints. That compliance burden becomes a competitive advantage: safer access, better provenance, and stronger alignment with European health data governance.
The company remains deeply embedded in the Paris ecosystem. It was incubated inside Owkin before spinning out, maintains a presence around Station F, and benefits from the cross-pollination between French AI and biotech communities. Its investor base reflects that positioning: Sofinnova Partners, Bpifrance, Cathay Innovation, Xavier Niel, and Frst provide a blend of life-science expertise, sovereign capital, and deep-tech conviction. In 2026, Bioptimus is the clearest European bet that foundation models can unlock biology at scale—and a contender to become the default AI layer for drug discovery in Europe.
StartupGrowthBiotechAIHealthcare
Stockholm, Sweden · StartupBrickanta is building an AI-native operating layer for early-stage commercial construction planning. The platform interprets drawings, code constraints, and cost data to automate bid analysis and estimation, reducing procurement risk and planning overhead for project owners and contractors.
StartupEarly StagePropTechConstruction TechAI
Stockholm, Sweden · AcceleratorEQT Ventures is the VC arm of EQT Group, launched in 2016 in Stockholm with offices in London, Berlin, and San Francisco. Managing over EUR 2.2B, the firm invests EUR 1-25M from seed through Series C in AI, fintech, mobility, and marketplaces. EQT Ventures uses Motherbrain, its proprietary AI deal-sourcing platform, to identify opportunities early. Portfolio includes Einride, Epidemic Sound, Voi, and Wolt. The fund leverages EQT's network of 300+ industrial advisors for strategic support.
AcceleratorEarly to GrowthAIFintechMobilityMarketplaces
Stockholm, Sweden · Venture CapitalKinnevik is a Stockholm-based growth-stage investment company listed on Nasdaq Stockholm that backs innovative digital businesses in healthcare, software, consumer, and climate sectors. Originally a traditional Swedish industrial conglomerate founded in 1936, Kinnevik transformed into a focused growth investor and was an early backer of companies like Zalando, Tele2, and Millicom. The firm manages a portfolio valued at several billion euros and takes concentrated positions in companies it believes can become category leaders. Kinnevik provides patient capital with a long-term orientation unusual among European growth investors.
Venture CapitalGrowth to Late StageGrowth EquityHealthcareConsumerSoftware
Stockholm, Sweden · StartupFounded in 2023, Lovable builds an AI-powered full-stack software development platform that converts natural-language prompts into deployable applications. The product generates real frontend and backend code, integrates directly with GitHub, and is used by both non-technical founders for MVP creation and enterprise teams for rapid prototyping.
StartupLate StageAIDevToolsSoftwareB2B SaaS
Zagreb, Croatia · StartupPhotomath is a Zagreb-founded edtech application that uses camera-based recognition and AI to solve mathematical problems step by step, helping students understand concepts rather than just providing answers. The app has been downloaded over 300 million times, making it one of the most popular education apps globally. Google acquired Photomath in 2023, integrating its technology into the broader Google education ecosystem. Founded in 2014 by Damir Sabol, Photomath stands as one of Croatia's most successful consumer technology products and a landmark example of AI-powered educational tools built in Southeast Europe.
StartupGrowthEdTechAIConsumer Tech
Loading comments...